OBERON and TITANIA were double-blind, placebo-controlled Phase III trials enrolling just over 2,300 patients with a history of two or more moderate or one or more severe COPD exacerbations in the ...
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 years and older, ...
—First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage— BRIDGEWATER, N ...
BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s AZN0.30%increase; up pointing triangle chief executive, Pascal Soriot. So the idea that he would stake his company’s ...
AstraZeneca (AZN) reported second-quarter earnings that topped Wall Street expectations, driven by strong demand for its blockbuster cancer medicines. Sales of breast cancer drug Enhertu climbed 31% ...
AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s next generation of oncology drugs. Earnings per share, excluding some ...
Q2 core EPS of $2.63 versus expectation of $2.48 AstraZeneca maintains 2026 and 2030 targets CEO Soriot affirms confidence in pipeline after trial failure Shares rise 1.7%, but are down about 7% for ...
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models ...
Wainua showed no effect in patients on stabilizer therapy Failure in heart-disease trial was unexpected by analysts Drug showed some benefit in subgroup taking drug as standalone Setback clouds ...
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results